Why ViewRay Crushed the Market on Thursday
Thursday was a fine day for radiation therapy device maker ViewRay (NASDAQ: VRAY) and its shareholders. The company announced a new supply deal that sent its stock price nearly 12% higher.
ViewRay and Australian privately-held oncology and cardiac healthcare services company GenesisCare announced jointly that they have entered into a master purchase agreement. Under the terms of the deal, GenesisCare will buy up to 14 of ViewRay's MRIdian MR-Guided Therapy Systems for its operations in both the U.K. and in Ft. Myers, Florida. This will give GenesisCare the capacity to provide radiation therapy to patients at three of its treatment centers in the former country, in addition to the U.S. location.
Neither company revealed the price nor the leading terms of the arrangement.
Source Fool.com
